PUBLIC COMPANY
save$BLTEBELITE BIO, INC
$BLTE161.94-3.92%San Diego, CA, USupdated 4h ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase3Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
- phase3A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
- phase3Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 23, 26SELLMATA NATHAN L.· Chief Scientific Officer−$62K↗
- Apr 23, 26SELLMATA NATHAN L.· Chief Scientific Officer−$44K↗
- Apr 23, 26SELLMATA NATHAN L.· Chief Scientific Officer−$26K↗
- Apr 23, 26SELLMATA NATHAN L.· Chief Scientific Officer−$21K↗
- Apr 23, 26SELLMATA NATHAN L.· Chief Scientific Officer−$9K↗
- Apr 23, 26SELLMATA NATHAN L.· Chief Scientific Officer−$4K↗
- Apr 22, 26SELLMATA NATHAN L.· Chief Scientific Officer−$44K↗
- Apr 22, 26SELLMATA NATHAN L.· Chief Scientific Officer−$43K↗
- Apr 22, 26SELLMATA NATHAN L.· Chief Scientific Officer−$24K↗
- Apr 22, 26SELLMATA NATHAN L.· Chief Scientific Officer−$18K↗
- Apr 22, 26SELLMATA NATHAN L.· Chief Scientific Officer−$17K↗
- Apr 22, 26SELLMATA NATHAN L.· Chief Scientific Officer−$13K↗
- Apr 22, 26SELLMATA NATHAN L.· Chief Scientific Officer−$5K↗
- Apr 22, 26SELLMATA NATHAN L.· Chief Scientific Officer−$4K↗
- Apr 22, 26SELLMATA NATHAN L.· Chief Scientific Officer−$3K↗
- Apr 21, 26SELLMATA NATHAN L.· Chief Scientific Officer−$55K↗
- Apr 21, 26SELLMATA NATHAN L.· Chief Scientific Officer−$52K↗
- Apr 21, 26SELLMATA NATHAN L.· Chief Scientific Officer−$36K↗
- Apr 21, 26SELLMATA NATHAN L.· Chief Scientific Officer−$13K↗
- Apr 21, 26SELLMATA NATHAN L.· Chief Scientific Officer−$10K↗
🐶 Hiring Signal
News
- City banks nearly $100M for next-gen RNAi drugsCo-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.biopharma_dive · 2mo ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that